A company that developed a blood test that detects dozens of types of cancer has acknowledged that about 400 of its customers were mistakenly told last month that they might have the disease.
The company, Grail, said in an emailed statement on Sunday that a vendor it works with had sent hundreds of letters with incorrect test results because of a “software configuration issue” that has since been resolved.
The letters went to customers who had recently purchased Grail’s Galleri test, which uses a blood draw to detect a cancer signal shared by 50 types of cancer and is available only by prescription.
The problem was not caused by inaccurate test results, Grail said.
More than half of the people who received the letter in error had not yet had their blood drawn for the test, the company said.
Persons:
Grail